Does anyone think that they are a value play now? If not now, at what price point? With the TEVA $ they have ~600mil cash and ~750 mil debt, but even if you assign albuferon a value of zero, the have the Lupus drug in PIII and a revenue stream form the DOD starting this year.
On a side note - I was a proponent of the January effect in micro bios. What a slap of reality from the market for that idea this year!